Kristin Fiorino – Refractory Gastroesophageal Reflux Disease With Upper Gastrointestinal (GI) Symptoms, Gastroparesis, and Chronic Constipation

Access Program Information

FDA currently allows patients 12 years of age and older with various gastrointestinal (GI)
conditions to be treated with Domperidone through the Expanded Access to Investigational
Drugs program. These conditions include gastroesophageal reflux disease with upper GI
symptoms, gastroparesis, and chronic constipation. Patients must have failed standard
therapies to be eligible to receive Domperidone. This program facilitates availability of
investigational drugs, (such as Domperidone) to patients with serious diseases or conditions
when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or
treat the patient’s disease or condition.